Wiseman M N, Elstob J E, Camm A J, Nathan A W
Mt. Sinai Medical Center, Cleveland, Ohio.
Pacing Clin Electrophysiol. 1990 Jun;13(6):767-75. doi: 10.1111/j.1540-8159.1990.tb02103.x.
One hundred and sixty-nine patients with a wide range of cardiac arrhythmias and who had been treated with chronic oral flecainide acetate were reviewed retrospectively. The most common arrhythmia was atrial fibrillation (32%), and 20% of the patient population had the Wolff-Parkinson-White syndrome. Five hundred and three treatment episodes were assessed, 254 with flecainide alone or in combination, mean duration 7.3 +/- 9.4 months, and 249 without flecainide, mean duration 9.5 +/- 12.3 months. The most common dose for flecainide was 200 mg/day (57% of episodes), and it was used alone in 82% of flecainide treatment episodes. Arrhythmia frequency was reduced or abolished in 73% of flecainide treatment episodes, with little difference between arrhythmia groups. Unwanted effects were seen in 14% of flecainide treatment episodes, and half of these cases were managed by dose adjustment. It is concluded that flecainide acetate is effective in a wide range of cardiac arrhythmias, and that long-term management problems are few.
对169例患有各种心律失常且长期口服醋酸氟卡尼治疗的患者进行了回顾性研究。最常见的心律失常是心房颤动（32%），20%的患者患有预激综合征。评估了503个治疗疗程，其中254个疗程单独使用或联合使用氟卡尼，平均疗程7.3±9.4个月，249个疗程未使用氟卡尼，平均疗程9.5±12.3个月。氟卡尼最常用剂量为200mg/天（占疗程的57%），在82%的氟卡尼治疗疗程中单独使用。73%的氟卡尼治疗疗程中，心律失常频率降低或消失，各心律失常组之间差异不大。14%的氟卡尼治疗疗程出现了不良反应，其中一半病例通过调整剂量得到处理。结论是醋酸氟卡尼对各种心律失常有效，且长期管理问题较少。
